Fruzaqla for metastatic colorectal cancer in South Korea
Part of Cancer, Digestive system clinical trials.
This study monitors the safety and effectiveness of Fruzaqla (a targeted therapy taken as a pill) in adults with advanced colorectal cancer that has spread to other parts of the body. It is being done in South Korea to gather real-world information about how well the treatment works and how patients respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You are starting or already receiving Fruzaqla for your metastatic colorectal cancer, exactly as your doctor prescribes it in South Korea.
- You are willing and able to give written permission to be part of this study.
- You are not pregnant or breastfeeding.
- You are not currently taking part in any other clinical trial where you receive an experimental drug for your colorectal cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.